PROM1 and familial pancreatic carcinoma: It has been demonstrated that a subpopulation of CD133+ pancreatic cancer cells have CSCs characteristics and are highly chemo-resistance (2) Therefore, a suitable anticancer compound should be able to diminish CSCs as well as other cancer populations.